Diabetes Prevention Program (DPP)

Slides:



Advertisements
Similar presentations
What’s New in Type 2 Diabetes? Lots!
Advertisements

The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
1 Outcome evaluation of health promotion/life style change Wei-Chu Chie.
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Slide Source: Lipids Online Slide Library 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
The Diabetes Prevention Program 10 Year follow-up Long-term Follow-up to A Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
ADVICE. Advice Strongly advise adherence to diet and medication Smoking cessation, exercise, weight reduction Ensure diabetes education and advise Diabetes.
The Diabetes Prevention Program A U.S. Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
I CAN Prevent Diabetes! Individuals and Communities Acting Now to Prevent Diabetes Recruitment Discussion 2012.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Reducing the Risk of Developing Diabetes Chapter 5 Thomas Ransom, Ronald Goldenberg, Amanda Mikalachki, Ally PH Prebtani, Zubin Punthakee Canadian Diabetes.
Prevention of Type 2 Diabetes Mellitus
A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.
Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Preventing Type 2 Diabetes Selay Lam PGY1, Internal Medicine October 29, 2008.
1 Sarah Fowler Res. Professor of Biostat. & Epi. Director, Biostatistics Center PhD in Mathematical Statistics Specialties: statistical design, conduct,
Identifying and Treating Patients with Insulin Resistance
Reducing the Risk of T2DM: What Works?
Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
After eating, most food is turned into glucose, the body’s main source of energy. What Happens When We Eat? American Diabetes Association.
A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
A Diabetes Outcome Progression Trial
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
© American Medical Association. All rights reserved. Modifications to any data or analysis provided requires either AMA written permission or the.
Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Silaja Cheruvu, R3.  What’s the BEST way to prevent diabetes in high risk patients?  By doing nothing?  With lifestyle changes?  With medication?
CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.
Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.
Source: LIFESTYLE MODIFICATION IN THE PREVENTION OF TYPE 2 DIABETES: THE EXPERIENCE WITH THE DIABETES PREVENTION PROGRAM AND LOOK.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.
Sample slides for your use
Prediabetes: Targeting a population at risk
IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.
Medicare Diabetes Prevention Program
Copyright © 2011 American Medical Association. All rights reserved.
Placebo Metformin ***p < vs placebo
Sample slides for your use
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
Reducing the Risk of Developing Diabetes
Level of risk factor control in the overall sample and by gender
Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)
Offer the National DPP lifestyle change program to your patient population Thank you for considering the National Diabetes Prevention Program lifestyle.
Stratified analysis of the association between GDM and abdominal circumference (AC) >90th percentile at 28 wkGA. Stratified analysis of the association.
Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.
Glycemic control and body weight over 52 weeks.
Study design (A) and patient disposition (B).
Presentation transcript:

Diabetes Prevention Program (DPP) 3,234 men and women with impaired glucose tolerance (fasting plasma glucose 95–125 mg/dL and 2-hr postload glucose 140–199 mg/dL) and BMI 24 kg/m2 45% from minority groups with increased prevalence of type 2 diabetes: African Americans, Hispanic Americans, Asian Americans, and American Indians 27 centers nationwide Randomization to lifestyle changes to include at least 7% weight loss and exercise 150 min/wk, metformin 850 mg b.i.d., or placebo Primary endpoint: development of diabetes Follow-up: designed for 3.5–5 years, but discontinued 1 year early because of conclusive results (mean 2.8 years) The Diabetes Prevention Program (DPP) studied the onset of diabetes in 3,234 men and women with impaired glucose tolerance, defined as fasting plasma glucose 95–125 mg/dL (125 mg/dL or less in American Indian centers) and 2-hour postload glucose 140–199 mg/dL. Patients were 25 years of age or older and had body mass index (BMI) of 24 kg/m2 or higher (22 kg/m2 or higher in Asian Americans). Patients were randomized to intensive lifestyle intervention (reduction in body weight of at least 7% through diet and exercise, physical activity of moderate intensity for at least 150 min/week), metformin 850 mg twice daily plus standard lifestyle recommendations (diet, weight reduction, exercise), or placebo plus standard lifestyle recommendations. The primary endpoint was development of diabetes. The study was conducted in 27 centers nationwide and was designed to have a follow-up period of 3.5–5 years. More than 45% of patients were racial or ethnic minorities: 20% were African American, 16% Hispanic, 5% American Indian, and 4% Asian American. The patient population was 68% female, and 20% of patients were aged 60 years or older (overall mean age at baseline, 51±11 years). Mean baseline BMI was 34.0±6.7 kg/m2; BMI was 30 kg/m2 or greater in 68% of patients (57% of men and 73% of women). Mean fasting plasma glucose was 106.5±8.3 mg/dL, and mean postload glucose was 164.6±17.0 mg/dL. Diabetes Prevention Program. Diabetes Care 1999;22:623-634. Diabetes Prevention Program. Diabetes Care 2000;23:1619-1629.

Trial was discontinued 1 year early because of clear results DPP: Reduction in Incidence of Diabetes with Lifestyle Intervention or Metformin Trial was discontinued 1 year early because of clear results 29 31% reduction 22 58% reduction Patients Developing Diabetes in Mean 3-Year Follow-up (%) 14 The study was stopped 1 year early (mean follow-up 2.8 years) because the data were already conclusive. Compared with placebo, patients randomized to intensive lifestyle intervention had a 58% reduction in onset of type 2 diabetes (by 1997 American Diabetes Association criteria), which was significantly greater than the 31% reduction in the metformin group. Mean weight loss with intensive lifestyle intervention was 12 lb; 50% achieved the weight loss goal of 7% by the end of the 24-week instruction period, and 74% met the physical activity goal at that time. Daily calorie intake in this group was reduced by 450 kcal (vs. 296 kcal in the metformin group and 249 kcal in the placebo group), and total fat intake was reduced by 6.6% (vs. 0.8% in both the metformin and placebo groups). Diet + Exercise Metformin Placebo 5-7% reduction in body weight; exercise 30 min/d Knowler WC, et al. N Engl J Med 2002;346:393-403.

DPP: Cumulative Incidence of Diabetes p<0.001 for Lifestyle vs. Metformin, Lifestyle vs. Placebo, Metformin vs. Placebo 40 Placebo 30 Metformin Cumulative incidence (%) 20 Lifestyle 10 Diabetes developed in 14% of the intensive lifestyle intervention group, 22% of the metformin group, and 29% of the placebo group; based on these rates, an estimated 7 patients would need to be treated with intensive lifestyle intervention for 3 years to prevent 1 case of diabetes, compared with 14 patients treated with metformin. Treatment effects on incidence rates and risk reductions did not differ significantly among subgroups categorized by sex or ethnicity. However, intensive lifestyle intervention had a significantly greater effect in older patients, reducing the incidence of diabetes among patients older than 60 years by 69% compared with metformin and 71% compared with placebo. Intensive lifestyle intervention was also significantly more effective in patients with lower postload glucose levels at baseline and in patients with a lower BMI. An estimated 10 million Americans are at high risk for type 2 diabetes, which accounts for 95% of the 16 million cases of diabetes in the United States. Prevalence of the disease is almost 20% in individuals aged 60 and older, and is 60% higher in blacks and 90% higher in Hispanics than in whites. The dramatic threefold increase in prevalence in the past 30 years is due in large part to the increase in obesity; individuals with BMI of 30 kg/m2 or greater have a fivefold greater risk for diabetes than individuals with BMI of 25 kg/m2 or less. The results of the DPP are encouraging because they indicate that this trend can be reversed through intensive lifestyle intervention aimed at reducing obesity, and that this intervention works particularly well in older patients, who are at high risk for developing diabetes. References Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623-634. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000;23:1619-1629. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. 1 2 3 4 Years from randomization Knowler WC, et al. N Engl J Med 2002;346:393-403. ©2002 Massachusetts Medical Society.